Patient Preferences for Different Severities of and Treatments for Overactive Bladder

被引:29
|
作者
Wu, Jennifer M. [1 ]
Fulton, Rebekah G. [1 ]
Amundsen, Cindy L. [1 ]
Knight, Sharon K. [2 ,3 ]
Kuppermann, Miriam [2 ,3 ,4 ,5 ]
机构
[1] Duke Univ, Dept Obstet & Gynecol, Durham, NC 27707 USA
[2] Univ Calif San Francisco, Dept Obstet, Dept Gynecol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Reprod Sci, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Med Effect Res Ctr Diverse Populat, San Francisco, CA 94143 USA
来源
关键词
urge urinary incontinence; overactive bladder; utility; patient preferences; QUALITY-OF-LIFE; URINARY-INCONTINENCE; UTILITY SCORES; QUESTIONNAIRE; VALIDATION; MANAGEMENT; SYMPTOMS; OUTCOMES; COSTS;
D O I
10.1097/SPV.0b013e318223c8ad
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Symptoms of overactive bladder (OAB) can have profound effects on women's quality of life. However, quantitative data on how women value these symptoms and their treatments are limited. We sought to assess women's preferences, which are referred to as utilities, for different severities of and treatment options for OAB. Methods: Eighty women-40 with OAB symptoms and 40 without OAB-were recruited from urogynecology and urology practices at an academic institution from April to November 2009. A single, trained interviewer administered a computerized preference elicitation tool to measure preferences for 4 OAB severity levels (urgency/frequency and mild, moderate, and severe urge incontinence), as well as 3 OAB treatments with and without adverse effects or complications, which included (1) anticholinergic medications, (2) botulinum toxin injection, and (3) sacral neuromodulation. Preferences were assessed using the time trade-off (TTO) method. Results: Median TTO scores for OAB decreased as severity increased (urgency/frequency, 0.88; mild, 0.92; moderate, 0.85; severe, 0.73). Median TTO scores assigned to anticholinergic medications were higher (0.93) than those for botulinum (0.88) and sacral neuromodulation (0.85), and adverse effects or complications lowered the utilities for each treatment (anticholinergics, 0.88; botulinum, 0.75; and sacral neuromodulation, 0.78). Conclusions: Women view symptoms of OAB, particularly moderate or severe symptoms, as being quite burdensome. The degree of invasiveness and the number of adverse effect/complications are important contributors to the utilities that women assign to the various treatment options.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [21] Patient frailty and the burden of overactive bladder
    Athavale, A.
    Gooch, K.
    Walker, D. R.
    Suh, M.
    Scaife, J.
    Haber, A.
    Hadker, N.
    Dmochowski, R.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 : S86 - S86
  • [22] Why treat overactive bladder and not the patient?
    Payne, C
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 : 8 - 9
  • [23] UNDERSTANDING PATIENT EXPERIENCES WITH OVERACTIVE BLADDER
    Sitto, Hannah
    Brodsky, Casey
    Wittmann, Daniela
    Wallner, Lauren
    Streur, Courtney
    Dejonckheere, Melissa
    Stoffel, John
    Sarma, Aruna
    Clemens, J. Quentin
    Lane, Giulia
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E273 - E274
  • [24] Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder
    Beusterien, Kathleen
    Kennelly, Michael J.
    Bridges, John F. P.
    Amos, Kaitlan
    Williams, Mary Jo
    Vasavada, Sandip
    [J]. NEUROUROLOGY AND URODYNAMICS, 2016, 35 (08) : 1028 - 1033
  • [25] Overactive bladder treatments in early phase clinical trials
    Colli, Enrico
    Digesu, Giuseppe Alessandro
    Olivieri, Lorenza
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) : 999 - 1007
  • [26] Nonpharmacologic treatments for overactive bladder - Pelvic floor exercises
    Bo, K
    Berghmans, LCM
    [J]. UROLOGY, 2000, 55 (5A) : 7 - 11
  • [27] Optimizing Nonsurgical Treatments of Overactive Bladder in the United States
    Brucker, Benjamin M.
    Lee, Richard K.
    Newman, Diane K.
    [J]. UROLOGY, 2020, 145 : 52 - 59
  • [28] Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment
    Decalf, Veerle H.
    Huion, Anja M. J.
    Benoit, Dries F.
    Denys, Marie-Astrid
    Petrovic, Mirko
    Everaert, Karel C. M. M.
    [J]. DRUGS & AGING, 2017, 34 (08) : 615 - 623
  • [29] Older People’s Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment
    Veerle H. Decalf
    Anja M. J. Huion
    Dries F. Benoit
    Marie-Astrid Denys
    Mirko Petrovic
    Karel C. M. M. Everaert
    [J]. Drugs & Aging, 2017, 34 : 615 - 623
  • [30] Patient Education for Overactive Bladder in the Digital Era
    Rena D. Malik
    Casey G. Kowalik
    [J]. Current Bladder Dysfunction Reports, 2019, 14 : 186 - 190